Elisabeth Greiner

Partner

Dr. rer. nat. Mag. pharm.

Dr. Greiner joined df-mp in 2005 and is a member of the firm’s chemistry and pharmaceuticals practice groups. She is a partner in the firm since 2012 and has an in-depth scientific background in the area of pharmaceutical sciences, in particular in organic and medicinal chemistry, drug formulation and pharmacology. Dr. Greiner is authorized to represent clients before the German Patent and Trademark Office, the German Federal Patent Court, the European Patent Office as well as the European Intellectual Property Office.

+ 49 89 210 296 0
elisabeth.greiner@df-mp.com

Dr. Greiner joined df-mp in 2005 and is a member of the firm’s chemistry and pharmaceuticals practice groups. She is a partner in the firm since 2012 and has an in-depth scientific background in the area of pharmaceutical sciences, in particular in organic and medicinal chemistry, drug formulation and pharmacology. Dr. Greiner is authorized to represent clients before the German Patent and Trademark Office, the German Federal Patent Court, the European Patent Office as well as the European Intellectual Property Office.

practice areas.

Dr. Greiner’s practice focuses on prosecution, opposition and litigation matters concerning German and European patents. She has been involved in various multi-national patent disputes regarding patents in the above areas of technology. A further focus of Dr. Greiner’s work lies in rendering patent validity and infringement opinions in connection with freedom-to-operate und due diligence projects, as well as counselling clients in matters relating to supplementary protection certificates (SPCs) for pharmaceuticals in Europe.

 

Five IP-Stars go to the df-mp team
Five IP-Stars go to the df-mp team

df-mp is delighted that five partners have been awarded the…

First choice in the high-tech industry
First choice in the high-tech industry

df-mp is recommended in the current JUVE-Handbook with the highest…

admissions.

  • German Patent Attorney
  • European Patent Attorney
  • European Trademark Attorney
  • European Design Attorney

references and activities.

  • Author and co-author of numerous scientific publications in the field of organic and medicinal chemistry
  • Organizer of IP-workshops
  • Lecturer of IP-seminars at the MCI (Management Center Innsbruck, the entrepreneurial school, Austria)

curriculum vitae.

Since 2012
Since 2012

Partner at df-mp

Since 2008
Since 2008

Patent attorney at df-mp

2005-2008
2005-2008

Legal trainee at df-mp, the German Patent and Trademark Office (DPMA) and the German Federal Patent Court (BPatG)

2001-2005
2001-2005

Postdoctoral research fellow in the Laboratory of Medicinal Chemistry at the National Institute of Health (NIH) in Bethesda, MD, U.S.A.

1999-2000
1999-2000

Doctorate Degree (with honors) in Medicinal Chemistry from University of Innsbruck, Institute of Pharmacy, Austria

1996
1996

Degree (Mag.pharm. with honors) in Medicinal Chemistry from University of Innsbruck, Institute of Pharmacy, Austria

association memberships.

  

publications.

  • Greiner, E.; Schottenberger, H.; Wurst, K.; Schmidhammer, H.: Novel Class of Morphinans with Acrylonitrile Incorporated Substructures as Key Intermediates for non-Oxygen-Bridged Opioid Ligands. J. Am. Chem. Soc. 2001, 123, 3840-3841.
  • Greiner, E.; Atkinson, A.J.J.; Ayala, A.; Chrousos, G.P.; Contoreggi, C.; Eckelman, W.C.; Gold, P.W.; Habib, K.E.; Jacobson, A.E.; Webster, E.L.; Rice K.C.: Synthesis of Doubly 13C-Labelled Antalarmin Isotopomers for Pharmacokinetic Studies. J. Labelled Cpd. Radiopharm. 2002, 45, 637-645.
  • Greiner, E.; Prisinzano, T.; Johnson II, E.M.; Dersch, C.M.; Marcus, J.; Rothman, R.B.; Jacobson, A.E.; Rice, K.C.: Structure-activity relationship studies of highly selective inhibitors of the dopamine transporter: N-benzylpiperidine analogues of 1-[2-[bis(4-fluorophenyl)methoxy]ethyl]-4-(3-phenylpropyl)piperazine. J. Med. Chem. 2003, 46, 1465-1469.
  • Greiner, E.; Spetea, M.; Krassnig, R.; Schuellner, F.; Aceto, M.; Harris, L.S.; Traynor, J.R.; Woods, J.H.; Winger, G.; Coop, A.; Schmidhammer, H.: Synthesis and Biological Evaluation of 14-Alkoxymorphinans – Part 18 – N-Substituted 14-Phenylpropyloxymorphinan-6-ones with Unanticipated Agonist Properties: Extending the Scope of Common Structure-Activity Relationships. J. Med. Chem. 2003, 46, 1758-1763.
  • Jagoda, E.; Contoreggi, C.; Lee, M.; Kao, C.K.; Szajak, L.P.; Listwak, S.; Gold, P.W.; Chrousos, G.P.; Greiner, E.; Kim B.M., Jacobson, A.E.; Rice K.C.: Eckelman, W.: Autoradiographic visualization of corticotropin releasing hormone type 1 receptors with a nonpeptide ligand: Synthesis of [Br-76]MJL-1-109-2. J. Med. Chem. 2003, 46, 3559-3562.
  • Greiner, E.; Folk, J.E.; Jacobson, A.E.; Rice, K.C.: A novel and facile preparation of bremazocine enantiomers through optically pure N-norbremazocines. Bioorg. Med. Chem. 2004, 12, 223-238.
  • Seggewiss, R.; Lore, K.; Greiner E.; Magnusson M.K.; Price D.A.; Douek D.C.; Dunbar C.E.; Wiestner A.: Imatinib inhibits T-cell receptor-mediated T-cell proliferation and activation in a dose-dependent manner. Blood 2005, 15, 2473-2479.
  • Greiner, E.; Boos, T.L.; Prisinzano T.E.; De Martino, M.G.; Zeglis, B.; Dersch, C.M.; Marcus, J.; Partilla, J.S.; Rothman, R.B.; Jacobson, A.E.; Rice, K.C.: Design and Synthesis of Promiscuous High Affinity Monoamine Transporter Ligands: An Attempt at Unraveling Transporter Selectivity. J. Med. Chem. 2006 Mar 9;49(5):1766-72.
  • Weichsel R, Dix C, Wooldridge L, Clement M, Fenton-May A, Sewell AK, Zezula J, Greiner E, Gostick E, Price DA, Einsele H, Seggewiss R. Profound inhibition of antigen-specific T-cell effector functions by dasatinib. Clin Cancer Res. 2008 Apr 15;14(8):2484-91.